• PCN35 OUT OF POCKET EXPENSES FOR BREAST CANCER SURVIVORS- DIFFERENCES BY TIME SINCE DIAGNOSIS IN A RURAL POPULATION

    May 1, 2010, 00:00

  • PCN158 A METHOD TO INCREASE SAMPLE SIZE BY REMOVING THE CONTINUOUS ENROLLMENT REQUIREMENT

    May 1, 2010, 00:00

  • PCN53 RETROSPECTIVE US CLAIMS DATABASE ANALYSIS OF THE COST OF SEQUENCING OF SORAFENIB AND SUNITINIB IN THE TREATMENT OF PATIENTS WITH RENAL CELL CARCINOMA (RCC)

    May 1, 2010, 00:00

  • PND29 AN ASSESSMENT OF DISEASE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS RELATING TO BLADDER DYSFUNCTION USED IN PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2010, 00:00

  • PCN7 A COMPARISON OF INTRAVENOUS AND ORAL FORMULATIONS OF FLUDARABINE IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

    May 1, 2010, 00:00

  • PDB32 ECONOMIC AND HEALTH CONSEQUENCES OF THE USE OF A DPP4 PLUS METPHORMINE SCHEME IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN MEXICO FROM THE PRIVATE PERSPECTIVE

    May 1, 2010, 00:00

  • PDB11 RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES TREATED WITH EXENATIDE OR THIAZOLIDINEDIONES- A RETROSPECTIVE ANALYSIS OF THE PHARMETRICS DATABASE

    May 1, 2010, 00:00

  • PCV101 THE IMPACT OF MULTIPLE CARDIOVASCULAR DIEASES ON ANTIDIABETIC MEDICATION ADHERENCE IN A CALIFORNIA MEDICAID POPULATION WITH COMORBID TYPE II DIABETES AND CARDIOVASCULAR DISEASE

    May 1, 2010, 00:00

  • PCV145 IMPACT OF A SEMINAL STUDY ON PRACTICE PATTERNS- STATIN USE BEFORE AND AFTER THE JUPITER STUDY

    May 1, 2010, 00:00

  • PSY1 CONCORDANCE IN PATIENT REPORTED MEASURES OF OPIOID-RELATED SIDE EFFECTS COLLECTED FROM CHECKLIST VERSUS OPEN-TEXT FORMAT QUESTIONS

    May 1, 2010, 00:00

  • PCN75 COST-EFFECTIVENESS ANALYSIS OF EGFR MUTATION TESTING IN PATIENTS WITH ADVANCED NON SMALL-CELL LUNG CANCER (ANSCLC) TREATED WITH GEFITINIB OR CARBOPLATIN-PACLITAXEL

    May 1, 2010, 00:00

  • PMC12 RULING OUT EXTENDLY DOMINATED OPTIONS USING AN ICER MATRIX

    May 1, 2010, 00:00

  • PMH45 DAILY AVERAGE CONSUMPTION AND PHARMACY COSTS OF DULOXETINE ACROSS MULTIPLE INDICATIONS AMONG COMMERCIALLY INSURED PATIENTS

    May 1, 2010, 00:00

  • PMC1 EVALUATING CLINICIAN REPORTED OUTCOME (CRO) ENDPOINTS FOR FDA REGULATORY APPROVALS

    May 1, 2010, 00:00

  • PMC26 EVALUATING TREATMENT SATISFACTION ENDPOINT EVIDENCE FOR EMEA REGULATORY APPROVALS

    May 1, 2010, 00:00

  • PMS30 ADHERENCE TO DULOXETINE AND HOSPITAL UTILIZATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND CHRONIC PAIN

    May 1, 2010, 00:00

  • PCV38 RELATIONSHIP BETWEEN ADMITTING (NON-FASTING) BLOOD GLUCOSE AND IN-HOSPITAL MORTALITY STRATIFIED BY DIABETES MELLITUS AMONG ACUTE CORONARY SYNDROME PATIENTS IN OMAN

    May 1, 2010, 00:00

  • PIN46 FACTORS ASSOCIATED WITH SUBOPTIMAL ADHERENCE TO HUMAN IMMUNODEFICIENCY VIRUS THERAPY

    May 1, 2010, 00:00

  • PHP98 THE ROLE OF AUTHORIZED GENERICS IN THE PRESCRIPTION DRUG MARKETPLACE

    May 1, 2010, 00:00

  • PGI31 PAIN AFTER LIVER TRANSPLANT- A CROSS SECTIONAL STUDY

    May 1, 2010, 00:00

  • PRS9 COMPARISON OF CHRONIC BRONCHITIS IN ONTARIO, CANADA BETWEEN 2003 AND 2009

    May 1, 2010, 00:00

  • PMS45 ASSESSING HEALTH-RELATED QUALITY OF LIFE IN TAIWANESE RHEUMATOID ARTHRITIS PATIENTS BY APPLYING TIME-TRADE-OFF AND EQ-5D METHODS

    May 1, 2010, 00:00

  • PSS1 BEVACIZUMAB FOR NEO-VASCULAR AGE RELATED MACULAR DEGENERATION-EVIDENCE SUMMARY

    May 1, 2010, 00:00

  • PHP29 SPATIAL DEPENDENCE (OR CLUSTER) IN TOTAL NUMBER OF PRESCRIPTION DRUGS FILLED AT RETAIL PHARMACIES IN US

    May 1, 2010, 00:00

  • PMS17 ESTIMATION OF COSTS OF HEALTH CARE FOR PEOPLE WITH RHEUMATOID ARTHRITIS FOR VARYING DEGREES OF DISABILITY AS MEASURED BY THE HEALTH ASSESSMENT QUESTIONNAIRE IN THE UNITED KINGDOM

    May 1, 2010, 00:00

  • PDB1 ASSOCIATION BETWEEN GLYCOSYLATED HEMOGLOBIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS- A NESTED CASE-CONTROL STUDY

    May 1, 2010, 00:00

  • PMC8 THE EFFECT OF LENGTH OF OBSERVATION AND CLAIMS DATA TYPE ON ESTIMATES OF COMORBIDITIES AMONG MEDICAID BENEFICIARIES

    May 1, 2010, 00:00

  • PMC40 INSTIGATING AND ENCOURAGING INDIVIDUAL HEALTH BEHAVIORS THROUGH TECHNOLOGY- A TRANSTHEORETICAL PROPOSITION

    May 1, 2010, 00:00

  • PDB27 COST AND EFFECTIVENESS OF EDUCATIONAL STRATEGIES FOR THE CONTROL AND TREATMENT OF TYPE 2 DIABETES (DMT2) AND CARDIOVASCULAR RISK FACTORS (CVRF)

    May 1, 2010, 00:00

  • PMH7 TRENDS AND PATTERNS IN THE DIAGNOSIS AND PRESCRIBING OF PSYCHOTROPIC MEDICATIONS IN CHILDREN AND ADOLESCENTS WITH ADHD.

    May 1, 2010, 00:00

  • PMS31 AN EVENT-LEVEL ANALYSIS OF PRESCRIPTION REFILL INTERVALS FOR ADALIMUMAB AND ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PCN69 COST-EFFECTIVENESS OF LENOGRASTYM ON NEUTROPENIA DURATION IN CHILDREN RECEIVING CHEMOTHERAPY FOR LEUKEMIA

    May 1, 2010, 00:00

  • PSY41 PATIENT AND CAREGIVER-REPORTED SYMPTOMS AND REASONS FOR STARTING/STOPPING RECOMBINANT FACTOR VIIA (RFVIIA) TREATMENT- OBSERVATIONS FROM THE DOSING OBSERVATIONAL STUDY IN HEMOPHILIA (DOSE)

    May 1, 2010, 00:00

  • PHP60 RATIONAL USE EFFECTS OF IMPLEMENTING AN ESSENTIAL MEDICINES LIST

    May 1, 2010, 00:00

  • PND41 THE EFFECT OF MULTIPLE COMPARISONS ADJUSTMENTS IN ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE BY WORK STATUS

    May 1, 2010, 00:00

  • PDB69 OLDER PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES (T2DM) EXPERIENCE MORE DELAYED TREATMENT WITH ORAL ANTIHYPERGLYCEMIC AGENTS COMPARED WITH YOUNGER PATIENTS

    May 1, 2010, 00:00

  • PIH14 COST-EFFECTIVENESS OF A HIGHLY PURIFIED HUMAN MENOPAUSAL GONADOTROPIN (HP-HMG) VERSUS RECOMBINANT FOLLICLESTIMULATING HORMONE (RFSH) IN PATIENTS PARTICIPATING IN AN ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) PROGRAM

    May 1, 2010, 00:00

  • PUK14 CHALLENGES IN ASSESSING COST-EFFECTIVENESS OF THERAPIES FOR DIALYSIS PATIENTS- A CASE STUDY OF SEVELAMER FOR THE TREATMENT OF HYPERPHOSPHATEMIA

    May 1, 2010, 00:00

  • PHP61 WILLINGNESS TO PAY FOR PHARMACY SERVICES- A REVIEW

    May 1, 2010, 00:00

  • PCN136 THE IMPACT OF PROSTATE CANCER AMONG CAUCASIAN AND AFRICAN AMERICANS IN A HOSPITALIZED SETTING

    May 1, 2010, 00:00

  • PMS13 INCREMENTAL MEDICAL COST OF MUSCOLOSKELETAL DISORDERS IN THE UNITED STATES- ESTIMATES FROM 2006 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA

    May 1, 2010, 00:00

  • PCN155 TREATMENT PATTERN OF METASTATIC TRIPLE NEGATIVE BREAST CANCER IN COMMUNITY PRACTICE

    May 1, 2010, 00:00

  • PCN122 HPV VACCINE COVERAGE AND ADOPTION ACROSS THE UNITED STATES

    May 1, 2010, 00:00

  • PHP51 CONSUMER KNOWLEDGE AND BELIEFS REGARDING ANTIBIOTIC RESISTANCE- A TELEPHONE SURVEY AND FOCUS GROUP INTERVIEW

    May 1, 2010, 00:00

  • PHP46 THE FINANCIAL IMPACT OF MEDICATION RECONCILIATION TO REDUCE DRUG-RELATED PROBLEMS

    May 1, 2010, 00:00

  • PCN91 VALIDATION OF HEALTH OUTCOMES RESEARCH OF CANCER

    May 1, 2010, 00:00

  • PCV51 AN ASSESSMENT OF DIRECT COSTS OF SINGLE PILL VERSUS FREE COMBINATION ARB/CCB THERAPY IN PATIENTS WITH HYPERTENSION

    May 1, 2010, 00:00

  • PHP75 A FRAMEWORK TO ASSIST PHARMACEUTICAL COMMERCIALIZATION TEAMS IN EFFICIENTLY ALLOCATING RESOURCES TO GENERATE EVIDENCE OF PRODUCT VALUE TO SUPPORT GLOBAL MARKET ACCESS ACROSS DIVERSE PAYER ENVIRONMENTS

    May 1, 2010, 00:00

  • CASE1 IMPLEMENTATION OF A NONFORMULARY PRESCRIBING MONITORING SYSTEMS REVEALS OPPORTUNITIES FOR COST SAVINGS IN AN ACADEMIC MEDICAL CENTER

    May 1, 2010, 00:00

  • PUK11 COST-EFFECTIVENESS ANALYSIS OF DUTASTERIDE, TAMSULOSIN AND COMBINATION THERAPY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    May 1, 2010, 00:00

  • CN2 USE OF LATENT VARIABLE AND SURVIVAL MODELING TO ESTIMATE THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES AND PROGRESSION-FREE SURVIVAL IN MALIGNANT PLEURAL MESOTHELIOMA

    May 1, 2010, 00:00

  • CE4 A PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF TARGETED VACCINATION POLICIES TO MITIGATE THE IMPACT OF THE H1N1 PANDEMIC IN THE US

    May 1, 2010, 00:00

  • PHP50 DRUGS CHEAPER THAN THREEPENNY- THE MARKET OF EXTREMELY LOW-PRIZED DRUGS WITHIN THE NATONAL HEALTH INSURANCE IN TAIWAN

    May 1, 2010, 00:00

  • PMS60 UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO

    May 1, 2010, 00:00

  • PMH81 ANTIPSYCHOTIC USE IN SENIORS- AN ANALYSIS FOCUSING ON DRUG CLAIMS FROM 2001 TO 2007

    May 1, 2010, 00:00

  • PMC38 DETERMINING MISSING DATA RULES FOR PROS- ALPHA-IF-ITEM-DELETED

    May 1, 2010, 00:00

  • PHP107 THE HEALTH ECONOMIC IMPACT OF ORAL NUTRITIONAL SUPPLEMENTS IN THE HOSPITAL SETTING IN GERMANY

    May 1, 2010, 00:00

  • PCN95 COST-EFFECTIVENESS OF SEROTONIN-TYPE 3 RECEPTOR ANTAGONISTS FOR CHEMOTHERAPY-INDUCED EMESIS IN NON SMALL CELL LUNG CANCER PATIENTS RECEIVING CISPLATIN-BASED CHEMOTHERAPY

    May 1, 2010, 00:00

  • PMS1 ASSESSMENT OF COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)-FINDINGS FROM A RETROSPECTIVE CLAIMS DATABASE ANALYSIS USING A PRE-PROGRAMMED DATA ANALYSIS TOOL

    May 1, 2010, 00:00

  • PSY19 MULTIPLE MYELOMA- PATIENT OUT-OF-POCKET COSTS AND HEALTH-CARE UTILIZATION

    May 1, 2010, 00:00

  • PSY2 PREDICTORS OF OBESITY MEDICATION USE IN AMBULATORY SETTING- NAMCS 2006-07 ANALYSIS

    May 1, 2010, 00:00

  • PCV140 UNDERSTANDING THE CURRENT LIPID PROFILE, TREATMENT, AND CASE MIX OF PATIENTS WITH DYSLIPIDEMIA IN A REAL-WORLD POPULATION

    May 1, 2010, 00:00

  • PIN43 MENINGITIS VACCINE COVERAGE AND ADOPTION ACROSS THE UNITED STATES

    May 1, 2010, 00:00

  • PMC11 CAP DATABASE-PROVISION OF OUTPATIENT PROCEDURE DATA IN A UNIFIED, STANDARDIZED LANGUAGE

    May 1, 2010, 00:00

  • PCASE2 DEVELOPING CRITERIA FOR USE FOR CONTINUOUS GLUCOSE MONITORING (CGM) SENSORS IN A VETERAN POPULATION

    May 1, 2010, 00:00

  • PMH85 IMPACT OF FDA ANTIDEPRESSANT BLACK BOX WARNING AND OTHER REGULATORY CHANGES ON PRESCRIPTION PATTERN FOR CHILDREN BY OFFICE BASED PHYSICIANS USING NATIONAL AMBULATORY MEDICAL CARE SURVEY (NAMCS)

    May 1, 2010, 00:00

  • PDB36 ASSESSING THE IMPACT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN) RELATED HEALTH IMPAIRMENT ON LOSS OF PRODUCTIVE TIME (LOPT)

    May 1, 2010, 00:00

  • PHP73 IMPACT OF PHARMACEUTICAL REFORM AND ISSUES INVOLVED IN SOUTH KOREAS NHI

    May 1, 2010, 00:00

  • PDB70 EVALUATION OF SITAGLIPTIN DOSING AMONG RENAL IMPAIRED TYPE 2 DIABETES MELLITUS PATIENTS

    May 1, 2010, 00:00

  • PCN71 COST EFFECTIVENESS ANALYSIS OF BREAST CANCER RISK REDUCTION THERAPY- COMPARING TAMOXIFEN AND RALOXIFENE

    May 1, 2010, 00:00

  • PCN52 HEALTH CARE COSTS ASSOCIATED WITH MULTIKINASE INHIBITORS (MKIS) FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN A CLINICAL PRACTICE SETTING IN ITALY

    May 1, 2010, 00:00

  • PMH68 A LONGITUDINAL ANALYSIS OF THE EFFECT OF BUPRENORPHINE-MEDICATION ASSISTED TREATMENT (B-MAT) AND A STRUCTURED PATIENT SUPPORT PROGRAM ON B-MAT ADHERENCE IN A NATIONAL SAMPLE OF OPIOID DEPENDENT PATIENTS

    May 1, 2010, 00:00

  • PIN12 THE COST OF TUBERCULOSIS CONTROL IN THE ADULT POPULATION OF THE REPUBLIC OF ARMENIA, 2006

    May 1, 2010, 00:00

  • PMH56 ADULT ATTENTION DEFICIT HYPERACTIVITY DISORDER, LABOR FORCE STATUS AND WORKPLACE ABSENTEEISM AND PRESENTEEISM

    May 1, 2010, 00:00

  • PMH3 DESCRIPTIVE UNDERSTANDING OF DIAGNOSED OPIOID MISUSERS VERSUS OTHER OPIOID USERS

    May 1, 2010, 00:00

  • PIN41 UNDERSTANDING CHILDRENS PREFERENCES FOR INFLUENZA VACCINES USING CONJOINT ANALYSIS

    May 1, 2010, 00:00

  • PCV42 INPATIENT MORTALITY AND HOSPITALIZATION COSTS IN ATRIAL FIBRILLATION PATIENTS

    May 1, 2010, 00:00

  • PCN156 IMPROVING ASCERTAINMENT OF VITAL STATUS USING SOCIAL SECURITY DEATH MASTER FILE (SSDMF) AND THE NATIONAL DEATH INDEX (NDI)

    May 1, 2010, 00:00

  • PIH2 THE PREVALENCE AND USE OF POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY POPULATION USING NATIONAL NURSING HOME SURVEY

    May 1, 2010, 00:00

  • PSY44 DAILY ASSESSMENT OF OUTCOMES CAPTURING HOME TREATMENT OF CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI)- DESIGN, DISPOSITION AND IMPLICATIONS OF THE DOSING OBSERVATIONAL STUDY IN HEMOPHILIA (DOSE)

    May 1, 2010, 00:00

  • PSY47 OBESITY- AND WEIGHT-SPECIFIC HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR OBESE CHILDREN AND ADOLESCENTS

    May 1, 2010, 00:00

  • PHP70 ARE GOVERNMENT BASED REIMBURSEMENT PROGRAMS PERCEIVED BETTER OR WORSE COMPARED TO COMMERCIAL MANAGED CARE INSURANCE PAYERS BY PHARMACISTS?

    May 1, 2010, 00:00

  • PSY23 A COST-EFFECTIVENESS ANALYSIS OF CONVENTIONAL TREATMENT VERSUS BARIATRIC SURGERY FOR OBESE PATIENTS WITH TYPE-2 DIABETES AND HYPERTENSION AS COMORBIDITIES. PRELIMINARY RESULTS UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

    May 1, 2010, 00:00

  • PSS3 THE ECONOMIC IMPACT OF DRY EYE DISEASE IN THE UNITED STATES

    May 1, 2010, 00:00

  • PCN80 A SYSTEMIC REVIEW OF COST-EFFECTIVENESS OF PROSTATESPECIFIC ANTIGEN (PSA) IN PROSTATE CANCER SCREENING

    May 1, 2010, 00:00

  • PCV5 ADVERSE EVENT ANALYSIS FOR MEDICARE PATIENTS WHO UNDERWENT HIP FRACTURE SURGERY AND SUFFERED VENOUS THROMBOEMBOLISM

    May 1, 2010, 00:00

  • PCV69 COST-EFFECTIVENESS ANALYSIS OF THE USE OF ROSUVASTATIN IN PREVENTION OF VASCULAR EVENTS IN THE MEXICAN POPULATION BASED ON THE JUPITER STUDY

    May 1, 2010, 00:00

  • PDB7 GLYCAEMIC CONTROL AND INSULIN UTILISATION IN PATIENTS WITH TYPE 2 DIABETES INITIATED ON A LONG-ACTING INSULIN ANALOGUE IN A DUTCH REAL-LIFE SETTING

    May 1, 2010, 00:00

  • PCV100 INTERVENTIONS TO IMPROVE COMPLIANCE WITH LIPID LOWERING MEDICATIONS- A SYSTEMATIC REVIEW OF THE LITERATURE

    May 1, 2010, 00:00

  • PHP86 DEVELOPING GLOBAL ROAD MAPS FOR REIMBURSEMENT PROCESSES USED IN HEALTH TECHNOLOGY ASSESSMENT- PHARMACEUTICALS, MEDICAL DEVICES, AND DIAGNOSTICS

    May 1, 2010, 00:00

  • PHP35 LOOKING FOR A COST-EFFECTIVENESS THRESHOLD IN KOREA

    May 1, 2010, 00:00

  • PHP96 TRENDS IN PREVENTABLE HOSPITALIZATION PATTERNS IN THE US- EXAMINING SMALL AREA VARIATION IN PRIMARY CARE PERFORMANCE IN THE LAST DECADE

    May 1, 2010, 00:00

  • PMS67 TWO YEAR MAINTENANCE INFLIXIMAB DOSING AND ADMINISTRATION PATTERNS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PCV92 ARE DOUBLE-BLIND, DOUBLE-DUMMY STUDIES SUITABLE FOR RESOURCE UTILISATION ANALYSES? AN EXAMPLE FROM A NEW ORAL ANTICOAGULANT FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) FOLLOWING ORTHOPAEDIC SURGERY

    May 1, 2010, 00:00

  • PMS69 DISPARITIES IN DISEASE MODIFYING ANTI-RHEUMATOID TREATMENT IN RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PIN50 METHODS TO IDENTIFY AND COMPARE BLOODSTREAM INFECTION RATES AMONG PATIENTS ADMINISTERED PARENTERAL NUTRITION VIA HOSPITAL COMPOUNDED VS. PREMIXED MULTI-CHAMBER BAGS

    May 1, 2010, 00:00

  • PMH49 COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS AS ADJUNCTIVE THERAPY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

    May 1, 2010, 00:00

  • PMC33 THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D ELECTRONIC VERSION (EQ-5D EPRO)

    May 1, 2010, 00:00

  • RM1 COMPARATIVE PERFORMANCE OF RISK ADJUSTMENT MEASURES IN A SAMPLE OF COMMERCIALLY-INSURED PATIENTS UNDER AGE 65- TWO SIMPLE MEASURES OUTPERFORM CURRENT STANDARDS

    May 1, 2010, 00:00

  • PIH13 HEALTH CARE UTILIZATION AND COSTS FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER

    May 1, 2010, 00:00

  • PGI16 PATTERNS OF LUBIPROSTONE UTILIZATION AND COSTS IN MEMBERS OF A LARGE HEALTH BENEFITS COMPANY

    May 1, 2010, 00:00

  • PMS26 COSTS OF VERTEBROPLASTY AND KYPHOPLASTY FROM THE HOSPITAL PERSPECTIVE

    May 1, 2010, 00:00

  • PHP114 A TOOL FOR COST-MINIMIZATION STUDIES IN ANESTHESIA IN COLOMBIA

    May 1, 2010, 00:00

  • PCN9 USING PROPENSITY SCORES TO REDUCE SELECTION BIAS IN AN OBSERVATIONAL STUDY COMPARING RASBURICASE TO ALLOPURINOL IN THE US

    May 1, 2010, 00:00

  • PMH93 AGREEMENT BETWEEN PATIENTS WITH MILD DEMENTIA AND CAREGIVERS ON THE PROMIS CAT MEASURE OF PERCEIVED COGNITIVE FUNCTION

    May 1, 2010, 00:00

  • PSS4 COST EFFECTIVENESS ANALYSIS OF THE ACRYSOF CACHET PHAKIC INTRAOCULAR LENS

    May 1, 2010, 00:00

  • PMH27 ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD) - BUDGET IMPACT ANALYSIS

    May 1, 2010, 00:00

  • PDB16 IMPACT OF NOVOLOG EXTENDED DRUG STABILITY ON HEALTH PLAN EXPENDITURES FOR INSULIN AND SUPPLIES IN PUMP USERS

    May 1, 2010, 00:00

  • CE3 COST-EFFECTIVENESS OF POLYMYXIN B IMMOBILIZED FIBER COLUMN AND CONVENTIONAL MEDICAL THERAPY IN THE MANAGEMENT OF SEVERE ABDOMINAL SEPSIS IN ITALY

    May 1, 2010, 00:00

  • PMS58 HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO

    May 1, 2010, 00:00

  • HT1 COMPARATIVE-EFFECTIVENESS VERSUS COST-EFFECTIVENESS- A COMPARISON OF THE FRENCH AND SCOTTISH APPROACHES TO SINGLE TECHNOLOGY ASSESSMENT (STA)

    May 1, 2010, 00:00

  • PIN4 IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) ON LIFE EXPECTANCY AND QUALITY-ADJUSTED LIFE-YEARS (QALYS) IN CHRONIC HEPATITIS C (CHC) PATIENTS

    May 1, 2010, 00:00

  • PGI4 SYSTEMATIC REVIEW AND META-ANALYSIS OF PUBLISHED RANDOMIZED CONTROLLED TRIALS COMPARING THE EFFICACY OF PEGINTERFERON-ALPHA-2A VERSUS PEGINTERFERON ALPHA-2B BOTH PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS

    May 1, 2010, 00:00

  • PCN146 REAL WORLD DATA ON MULTIPLE MYELOMA (MM) TREATMENT IN BRAZIL- GUIDANCE FOR THE PRIVATE HEALTH CARE SYSTEM (PHS)

    May 1, 2010, 00:00

  • PUK8 ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION AND COSTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS FROM TWO LARGE CLAIMS DATABASES

    May 1, 2010, 00:00

  • PCN20 INFUSION REACTIONS IN PATIENTS TREATED WITH ANTI-EGFR MONOCLONAL ANTIBODY THERAPIES FOR METASTATIC COLORECTAL CANCER- RATES AND IMPACT FROM LITERATURE REVIEW

    May 1, 2010, 00:00

  • PRS44 ANTIBIOTIC PRESCRIBING FOR ACUTE RESPIRATORY TRACT INFECTIONS IN ADULT PRIMARY CARE- IS GOOD INSURANCE BAD FOR ANTIBIOTIC PRESCRIBING?

    May 1, 2010, 00:00

  • PMH66 REASONS FOR CONTINUING OR DISCONTINUING OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA FROM PATIENTS PERSPECTIVES

    May 1, 2010, 00:00

  • PRS38 DRUG PRESCRIBING PATTERN IN AMBULATORY CARE SETTINGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN 2006-2007

    May 1, 2010, 00:00

  • PIN6 COST-ANALYSIS OF LEVOFLOXACIN IV COMPARED TO OTHER GUIDELINE-ENDORSED THERAPIES FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2010, 00:00

  • PIN44 UNINFECTED CHILDREN OF HIV-INFECTED AND UNINFECTED PARENT(S)- A COMPARATIVE ANALYSIS OF HEALTH CARE UTILIZATION AND HEALTH STATUS

    May 1, 2010, 00:00

  • PHP37 THE USE OF COMPARATIVE EFFECTIVENESS INFORMATION BY FORMULARY DECISION-MAKERS

    May 1, 2010, 00:00

  • PCN139 OPTIMISING MARKET ACCESS FOR ONCOLOGY DRUGS IN BRAZIL CHINA

    May 1, 2010, 00:00

  • PHP94 ASSOCIATION OF SURGEON AND HOSPITAL CHARACTERISTICS AND PRESENCE OF A PERIOPERATIVE CARE PATHWAY FOR ELECTIVE BOWEL RESECTION WITH LENGTH OF STAY AFTER LAPAROSCOPIC SURGERY; RESULTS OF A NATIONAL SURVEY

    May 1, 2010, 00:00

  • PCV37 VENOUS THROMBOEMBOLISM IN THE SINGAPOREAN POPULATION- THE NEED TO REVISIT RISK ASSESSMENT TOOLS FOR PROPHYLAXIS

    May 1, 2010, 00:00

  • PMS46 STATISTICAL DATA ANALYSIS OF DIAGNOSIS RELATED GROUP 244- BONE DISEASES AND SPECIFIC ARTHROPATHIES WITH COMPLICATIONS

    May 1, 2010, 00:00

  • PCN135 CONTROLLING THE COST OF CARE OF BREAST CANCER PATIENTS IN GERMANY USING CLINICAL PATHWAYS

    May 1, 2010, 00:00

  • PMS50 EXAMINATION OF PATIENT CHARACTERISTICS, COMORBIDITIES AND CONCOMITANT MEDICATION USE IN TWO DISTINCT PATIENT POPULATIONS WITH RHEUMATOID ARTHRITIS (RA) USING A VALIDATED DATA ANALYSIS TOOL

    May 1, 2010, 00:00

  • HE3 CAN INNOVATION BE REWARDED WITH THE APPLICATION OF RIGID COST-EFFECTIVENESS THRESHOLDS? THE HER2VE BREAST CANCER CASE STUDY

    May 1, 2010, 00:00

  • PSS10 COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS- ANALYSIS FROM THE ACCEPT TRIAL

    May 1, 2010, 00:00

  • PSS19 DEVELOPMENT OF A DECISION-ANALYTIC MODEL FOR GLAUCOMA PROGRESSION USING PATIENT LEVEL DATA FROM THREE LARGE RANDOMIZED CONTROLLED TRIALS

    May 1, 2010, 00:00

  • PRS43 PRESCRIBING ANTIBIOTICS FOR ACUTE RESPIRATORY TRACT INFECTIONS BY PRIMARY CARE PHYSICIANS IN NEW DELHI, INDIA

    May 1, 2010, 00:00

  • PND32 ANALYSIS OF DULOXETINE UTILIZATION AMONG COMMERCIALLY-INSURED FIBROMYALGIA PATIENTS

    May 1, 2010, 00:00

  • PCV148 RELATIONSHIP BETWEEN VENOUS THROMBOEMBOLISM AND HOSPITAL QUALITY

    May 1, 2010, 00:00

  • PMS7 COST ANALYSIS OF RECENTLY APPROVED AND OLDER ANTI-TNF BIOLOGIC AGENTS USED IN RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • HT4 PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL- IS IT REALISTIC?

    May 1, 2010, 00:00

  • PRS28 COST-UTILITY ANALYSES OF DISEASE-MODIFYING THERAPIES FOR PATIENTS WITH RELAPSE-REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATE

    May 1, 2010, 00:00

  • PCV88 ECONOMIC EVALUATION OF THE USE OF REGADENOSON IN MYOCARDIAL PERFUSION IMAGING- CARDIOVASCULAR LABORATORY PERSPECTIVES

    May 1, 2010, 00:00

  • CV4 COMPARATIVE COST OF ABLATION IN ATRIAL FIBRILLATION PATIENTS STRATIFIED BY PROCEDURAL SUCCESS VERSUS FAILURE- IMPLICATIONS FOR RESOURCE UTILIZATION IN MEDICARE-AGED ABLATION CANDIDATES IN THE UNITED STATES

    May 1, 2010, 00:00

  • PMH36 ESTIMATED UNITED STATES INCIDENCE AND COST OF EMERGENCY DEPARTMENT STAFF ASSAULTS PERPETRATED BY AGITATED ADULT PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER

    May 1, 2010, 00:00

  • PCV83 ECONOMIC ANALYSIS OF ENDOVASCULAR STENTING FOR PERIPHERAL ARTERIAL DISEASE IN LONG LESIONS OF THE SUPERFICIAL FEMORAL ARTERY

    May 1, 2010, 00:00

  • PCN90 BORTEZOMIB IS COST-EFFECTIVE FOR FIRST-LINE TREATMENT OF MULTIPLE MYELOMA IN SWEDEN

    May 1, 2010, 00:00

  • PCV131 PREDICTORS OF COMPUTED TOMOGRAPHY USE FOR CORONARY ARTERY DISEASE PATIENTS IN EMERGENCY DEPARTMENTS IN THE UNITED STATES

    May 1, 2010, 00:00

  • PSY52 URBAN GREEN SPACE AND PARK EXPENDITURES AS PREDICTORS OF URBAN OBESITY

    May 1, 2010, 00:00

  • PCV41 A DECADE OF STATIN LABORATORY TEST MONITORING IN THE UNITED STATES (1997-2007)- A COHORT STUDY

    May 1, 2010, 00:00

  • PGI27 OPEN VERSUS LAPAROSCOPIC PROCEDURES FOR CHOLECYSTECTOMY SURGERY- A COST-UTILITY ANALYSIS, UNDER THE BRAZILIAN PUBLIC PAYER PERSPECTIVE

    May 1, 2010, 00:00

  • PCN10 ESTIMATION OF G-CSF EFFECTIVENESS IN REDUCING NEUTROPENIA HOSPITALIZATION AMONG NON-HODGKINS LYMPHOMA (NHL) PATIENTS TREATED WITH ANTHRACYCLINE-BASED CHEMOTHERAPY

    May 1, 2010, 00:00

  • PCN43 INITIAL COSTS OF TREATMENT AMONG STAGE IV PROSTATE CANCER (PCA) CHEMOTHERAPY PATIENTS IN SEER-MEDICARE

    May 1, 2010, 00:00

  • PRS27 COST-UTILITY ANALYSIS OF ANTI-SMOKING TREATMENTS

    May 1, 2010, 00:00

  • PGI5 A META-ANALYSIS OF THE 5-HT3 RECEPTOR ANTAGONISTS USE IN POST-OPERATIVE NAUSEA AND VOMITING PROPHYLAXIS

    May 1, 2010, 00:00

  • PMS34 CAPTURING DATA ON HEALTH CARE USE AND COSTS FOR PATIENTS WITH OSTEOARTHRITIS- AGREEMENT BETWEEN A PATIENT-COMPLETED QUESTIONNAIRE AND ADMINISTRATIVE RECORDS

    May 1, 2010, 00:00

  • PMC5 VALIDATING A WEB-BASED INCREMENTAL COST-EFFECTIVENESS SOFTWARE PROGRAM THAT USES A MARKOV TRANSITION PROBABILITY MATRIX ANALYSIS MODEL

    May 1, 2010, 00:00

  • PGI35 PROTON PUMP INHIBITOR USE IN SENIORS- AN ANALYSIS FOCUSING ON DRUG CLAIMS 2001 TO 2008

    May 1, 2010, 00:00

  • PCN76 COST-EFFECTIVENESS OF WHITE BLOOD CELL GROWTH FACTOR USE AMONG ELDERLY NON-HODGKINS LYMPHOMA PATIENTS TREATED WITH CHEMOTHERAPY

    May 1, 2010, 00:00

  • PHP90 A DESCRIPTIVE STUDY OF PATIENTS ON FDA-CATEGORIZED INNOVATIVE DRUGS IN ANTICHOLESTEROL AND ANTIDIABETIC THERAPEUTIC CLASSES

    May 1, 2010, 00:00

  • PHP15 EVALUATION OF PATIENT ASSISTANCE PROGRAM AVAILABILITY AND ELIGIBILITY FOR TOP 200 BRAND AND GENERIC DRUGS IN THE UNITED STATES

    May 1, 2010, 00:00

  • PIN36 THE IMPACT OF AGE DEPENDENT UTILITY ON THE COST EFFECTIVENESS OF PEGYLATED INTERFERON AND RIBAVIRIN VERSUS INTERFERON AND RIBAVIRIN AS THERAPY FOR GENOTYPE I PATIENTS WITH CHRONIC HEPATITIS C

    May 1, 2010, 00:00

  • PCV103 A METHODOLOGY FOR USING CLAIMS DATA FROM ELECTRONIC PRESCRIBERS TO ASSESS FIRST FILL FAILURE RATE OF ANTIHYPERTENSIVE PRESCRIPTIONS

    May 1, 2010, 00:00

  • PHP33 REGIONAL INEQUALITIES IN THE UTILIZATION AND HEALTH INSURANCE REIMBURSEMENT OF SPA SERVICES IN HUNGARY

    May 1, 2010, 00:00

  • PCV9 CLINICAL RELEVANCE OF PHARMACOLOGICAL INTERACTIONS

    May 1, 2010, 00:00

  • PSS7 COMPARING FIXED-COMBINATION THERAPIES FOR TREATING PATIENTS WITH OPEN-ANGLE GLAUCOMA IN A MANAGED CARE ENVIRONMENT

    May 1, 2010, 00:00

  • PSY16 MEDICAL SERVICES UTILIZATION AND EXPENDITURE OF OBESITY-RELATED DISORDERS IN TAIWANESE ADULTS

    May 1, 2010, 00:00

  • PIN24 AN INITIAL COST-EFFECTIVENESS ANALYSIS OF THE NEW 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-I 3) VERSUS PCV-7 IN THE PUBLIC SECTOR OF HONG KONG

    May 1, 2010, 00:00

  • PHP105 THE UTILIZATION OF PARENTERAL NUTRITION IN THE UNITED STATES

    May 1, 2010, 00:00

  • PMS71 INDIRECT TREATMENT COMPARISONS OF BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS

    May 1, 2010, 00:00

  • PSS8 COST EFFICACY OF USTEKINUMAB IN TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN TURKEY

    May 1, 2010, 00:00

  • PGI7 LOW PREVALENCE OF HEPATITIS C VIRUS (HCV) DIAGNOSIS IN US HEALTH CARE DATA

    May 1, 2010, 00:00

  • PMH65 ADHERENCE AND PERSISTENCE TO TREATMENT IN PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ANALYSES WITH THE RAMQ DATABASE

    May 1, 2010, 00:00

  • PSY30 COST-EFFECTIVENESS OF BARIATRIC SURGICAL PROCEDURES VERSUS NO TREATMENT FOR MORBID OBESITY

    May 1, 2010, 00:00

  • PCV43 CLINICAL AND ECONOMIC IMPACT OF BIVALIRUDIN ON BLEEDING EVENTS IN HIGH RISK UNSTABLE ANGINA (UA)/NON-ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI) PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE

    May 1, 2010, 00:00

  • PCN12 HORIZON SCANNING TO SUPPORT PRIORITY-SETTING FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS

    May 1, 2010, 00:00

  • PSY28 COST-EFFECTIVENESS ANALYSIS OF CELECOXIB FOR THE MANAGEMENT OF LOW BACK PAIN AT THE SOCIAL SECURITY MEXICAN INSTITUTE

    May 1, 2010, 00:00

  • PCN89 COST EFFECTIVENESS ANALYSIS OF A CLINICAL PATHWAY FOR THE SURVEILLANCE OF HEPATOCARCINOMA IN COLOMBIA

    May 1, 2010, 00:00

  • PHP67 COMPARISON OF DRUG TYPES IN INCIDENT REPORTS AMONG TEACHING HOSPITALS IN JAPAN

    May 1, 2010, 00:00

  • PMH39 COST OF ILLNESS OF POST-TRAUMATIC STRESS DISORDER COMPARED WITH MAJOR DEPRESSIVE DISORDER

    May 1, 2010, 00:00

  • PIN38 COSTS OF RECRUITING PATIENTS WITH HIV INTO A RANDOMIZED CLINICAL TRIAL OF BEHAVIORAL INTERVENTIONS FOR ANTIRETROVIRAL MEDICATION ADHERENCE

    May 1, 2010, 00:00

  • PND21 INTERIM ANALYSIS OF A LARGE ONGOING PHASE IV PROSPECTIVE OBSERVATIONAL COHORT STUDY (MDS ON BOTOX UTILITY-MOBILITY) OF BOTULINUM TOXIN TYPE A ON HEALTH UTILITY IN PATIENTS RECEIVING TREATMENT FOR APPROVED THERAPEUTIC INDICATIONS IN CA ...

    May 1, 2010, 00:00

  • PRS49 COMPARISON OF TWO METHODS FOR COVARIATE ADJUSTMENT WHEN ASSESSING HEALTH OUTCOMES IN THE U.S. HOSPITAL INPATIENT SETTING

    May 1, 2010, 00:00

  • PHP62 A MODEL TO ESTIMATE INCREASE IN REVENUE FROM IMPLEMENTING MEDICATION ADHERENCE MANAGEMENT SERVICES IN COMMUNITY PHARMACIES

    May 1, 2010, 00:00

  • DB2 EVALUATION OF AGREEMENT BETWEEN INTERNET-BASED SELF- AND PROXY-REPORTED HEALTH CARE UTILIZATION AND ADMINISTRATIVE HEALTH CARE CLAIMS

    May 1, 2010, 00:00

  • CASE3 THE VA TECHNOLOGY ASSESSMENT ADVISORY GROUP- INFORMING EVIDENCE-BASED POLICY RECOMMENDATIONS FOR ROBOTIC PROSTATECTOMY

    May 1, 2010, 00:00

  • PCN74 COST-EFFECTIVENESS OF PROMOTORA LED HEALTH EDUCATION INTERVENTIONS TO INCREASE CERVICAL CANCER SCREENING AMONG LOW INCOME HISPANIC WOMEN

    May 1, 2010, 00:00

  • PCV40 HEALTH DISPARITIES IN MODIFIABLE RISK FACTORS FOR CORONARY HEART DISEASE- A COMPARISON OF APPALACHIAN TO NONAPPALACHIAN PORTIONS OF APPALACHIAN STATES

    May 1, 2010, 00:00

  • PIH20 THE PSYCHOMETRIC PROPERTIES OF THE PERCEPTIONS OF CARE ADJECTIVE CHECK LIST-REVISED (PCACL-R) EVALUATED IN A LARGE UK MATERNITY CARE POPULATION

    May 1, 2010, 00:00

  • PDB55 THE IMPACT OF DIABETIC NON- SEVERE HYPOGLYCEMIC EPISODES ON FUNCTIONING AND DIABETES MANAGMENT- A 4 COUNTRY PERSPECTIVE

    May 1, 2010, 00:00

  • PCV72 COST-EFFECTIVENESS OF ROSUVASTATIN FOR THE PRIMARY PREVENTION OF VASCULAR EVENTS ACCORDING TO FRAMINGHAM RISK SCORE IN PATIENTS WITH AN ELEVATED C-REACTIVE PROTEIN

    May 1, 2010, 00:00

  • PGI33 CURRENT EVIDENCE REGARDING THE HEPATITIS C PATIENT EXPERIENCE

    May 1, 2010, 00:00

  • PIH32 HEALTH CARE ACCESS AND UTILIZATION AMONG UNITED STATES ADULTS BY CENSUS REGIONS

    May 1, 2010, 00:00

  • PCV113 IMPACT OF STROKE ETIOLOGY ON CARE NEED AND LONG-TERM OUTCOMES

    May 1, 2010, 00:00

  • PCN119 USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE WILLINGNESS TO PAY FOR CANCER TREATMENT IN KOREA- A GENERAL POPULATION STUDY

    May 1, 2010, 00:00

  • PIH21 VALIDATION AND COMPARISON OF EUROQOL AND SHORT FORM 6D IN CHINESE CHRONIC PROSTATITIS PATIENTS

    May 1, 2010, 00:00

  • PMH46 TREATMENT PERSISTENCE WITH DULOXETINE AND HEALTH CARE COSTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    May 1, 2010, 00:00

  • PHP63 ADVERSE DRUG REACTIONS AND COST IMPLICATED- NEED FOR VIGILANT MONITORING

    May 1, 2010, 00:00

  • PIH28 THE IMPACT OF MEDICARE PART D ON OUT-OF-POCKET DRUG EXPENDITURE OF THE ELDERLY

    May 1, 2010, 00:00

  • PDB64 USING DECISION MODELING TO DETERMINE COST-EFFECTIVENESS OF PHARMACIST INTERVENTIONS FOR PATIENTS WITH DIABETES

    May 1, 2010, 00:00

  • PHP69 CMS VS. NICE COVERAGE OF TECHNOLOGIES- HOW DO THEY COMPARE?

    May 1, 2010, 00:00

  • PIH17 COST-EFFECTIVENESS ANALYSIS OF FOUR EMBRYO TRANSFER STRATEGIES

    May 1, 2010, 00:00

  • PCN88 COST-EFFECTIVENESS OF LENOGRASTIM NEUTROPENIA DURATION IN ADULTS RECEIVING CHEMOTHERAPY FOR LEUKEMIA

    May 1, 2010, 00:00

  • PCV53 ALISKIREN COMBINED WITH ANGIOTENSIN II-RECEPTOR BLOCKERS (ARB) RESULTED IN BETTER OUTCOMES COMPARED TO ARB COMBINED WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEI)- RESULTS FROM A CLAIMS DATABASE ANALYSIS

    May 1, 2010, 00:00

  • PDB20 AN ANALYSIS OF DIFFERENCES IN COST QUARTILES FOR PATIENTS WITH TYPE 2 DIABETES IN A LARGE CLAIMS DATABASE WITH LINKED LABORATORY RESULTS

    May 1, 2010, 00:00

  • PND36 POTENTIAL BARRIERS TO HOME CARE USE AMONG PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2010, 00:00

  • PMH70 OPIOID RELAPSE RATES AMONG A SAMPLE OF NEW BUPRENORPHINE-MEDICATION ASSISTED TREATMENT PATIENTS- RELATIONSHIP TO MEDICATION COMPLIANCE AT ONE YEAR

    May 1, 2010, 00:00

  • PCASE6 THE FINANCIAL IMPACT OF A DAILY AVERAGE CONSUMPTION (DACON) ANALYSIS IN A US PHARMACY BENEFIT MANAGEMENT (PBM) COMPANY

    May 1, 2010, 00:00

  • PSY5 A META-ANALYSIS OF EFFICACY AND SAFETY OF PARECOXIB IN ORTHOPEDICS SURGERY

    May 1, 2010, 00:00

  • PMS61 ALTERNATIVE APPROACHES FOR ESTIMATING DRUG DOSING IN THE TREATMENT OF RHEUMATOID ARTHRITIS- THE CASE OF INFLIXIMAB

    May 1, 2010, 00:00

  • PIH3 RISK OF WEIGHT GAIN WITH THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) AND ATYPICAL ANTIPSYCHOTICS (SGA) COMBINATION TREATMENT IN CHILDREN AND ADOLESCENTS

    May 1, 2010, 00:00

  • PDB60 GAPS IN MEDICAID COVERAGE AND THE RISK FOR HOSPITALIZATION AND MORTALITY AMONG INDIVIDUALS WITH DIABETES IN A MEDICAID PROGRAM

    May 1, 2010, 00:00

  • PCN159 HFS 14- A SPECIFIC QUALITY OF LIFE SCALE FOR PATIENTS WITH HAND-FOOT SYNDROME

    May 1, 2010, 00:00

  • PCN54 LOWER HEALTH CARE RESOURCE UTILIZATION ASSOCIATED WITH MANAGING NILOTINIB RELATED ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS- EVIDENCE FROM A CLINICAL PRACTICE SETTING STUDY

    May 1, 2010, 00:00

  • PCV124 ANTIHYPERTENSIVE PHARMACOTHERAPY-PHYSICIAN PERSPECTIVES AND PRESCRIBING PATTERNS IN THREE SOUTH INDIAN HOSPITALS

    May 1, 2010, 00:00

  • PMH29 NATIONAL ESTIMATES OF THE INPATIENT BURDEN OF PEDIATRIC BIPOLAR DISORDER

    May 1, 2010, 00:00

  • PMC14 MEDICATION LABEL EVALUATION PROCESS MODEL- USING THE STRUCTURAL EQUATION MODELING APPROACH TO BETTER PREDICT PURCHASE INTENTION

    May 1, 2010, 00:00

  • PMS28 COST-UTILITY ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS USING A MARKOV MODEL

    May 1, 2010, 00:00

  • PCV6 A META-ANALYSIS OF EFFICACY OF ATORVASTATIN IN COMPARISON TO PRAVASTATIN, SIMVASTATIN AND ROSUVASTATIN FOR THE CONTROL OF DYSLIPIDEMIA AND CARDIOVASCULAR EVENTS PREVENTION

    May 1, 2010, 00:00

  • PCN101 INPATIENT RESOURCE UTILIZATION IN BRONCHIAL AND LUNG CANCER- ANALYSIS OF 2007 HEALTH CARE UTILIZATION AND PROJECT (HCUP) DATA

    May 1, 2010, 00:00

  • TR3 TIME-RELEASE LAUNCH IN RELATION TO GENERIC LAUNCH- CASES

    May 1, 2010, 00:00

  • PSY4 DAILY AVERAGE CONSUMPTION ANALYSIS OF LOW BACK PAIN AND OSTEOARTHRITIS PATIENTS USING OXYMORPHONE EXTENDED RELEASE AND OXYCODONE HYDORCHLORIDE CONTROLLED RELEASE TABLETS IN A COMMERCIALLY INSURED POPULATION

    May 1, 2010, 00:00

  • PRS4 ESTIMATION OF MORTALITY RISKS ATTRIBUTABLE TO COMORBIDITY IN COPD

    May 1, 2010, 00:00

  • PDB47 IMPROVING OUTCOMES AND PRODUCTIVITY FOR EMPLOYEES WITH DIABETES

    May 1, 2010, 00:00

  • PCN62 COST EFFECTIVENESS OF RADICAL PROSTATECTOMY VERSUS WATCHFUL WAITING FOR NON-SCREEN DETECTED PROSTATE CANCER- EXTRAPOLATING FROM THE SCANDINAVIAN TRIAL

    May 1, 2010, 00:00

  • PMS9 COST BURDEN OF SECOND FRACTURE IN PATIENTS WITH COMMERCIAL INSURANCE

    May 1, 2010, 00:00

  • PSY18 HEALTH CARE COSTS AND MEDICATION COMPLIANCE AMONG ELDERLY FIBROMYALGIA PATIENTS ON DULOXETINE VERSUS PREGABALIN

    May 1, 2010, 00:00

  • PDB44 A SYSTEMATIC REVIEW OF ADHERENCE, QUALITY OF LIFE AND MEDICAL COSTS IN FIXED-DOSE COMBINATION REGIMENS IN DIABETES

    May 1, 2010, 00:00

  • PCV132 COST-EFFECTIVENESS OF PERFUSION IMAGING WITH COMPUTED TOMOGRAPHY TO IDENTIFY PATIENTS FOR INTRAVENOUS THROMBOLYSIS- A HOSPITAL PERSPECTIVE

    May 1, 2010, 00:00

  • DB4 ACCOUNTING FOR THE RELATIONSHIP BETWEEN PER DIEM COST AND LOS WHEN ESTIMATING HOSPITALIZATION COSTS

    May 1, 2010, 00:00

  • PUK27 ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

    May 1, 2010, 00:00

  • PCV75 ROBUST UNIVARIATE AND MULTIVARIATE SENSITIVITY ANALYSIS CONFIRM THAT ENOXAPARIN IS COST-SAVING TO THE PAYERS COMPARED WITH UFH FOR VTE PREVENTION IN PATIENTS WITH ISCHEMIC STROKE- ANALYSIS OF THE PREVAIL DATA

    May 1, 2010, 00:00

  • PDB41 BELIEFS AND EXPECTATIONS ABOUT DIABETES AND MEDICATION ADHERENCE IN PERSONS WITH TYPE 2 DIABETES

    May 1, 2010, 00:00

  • PRS40 THE IMPACT OF THE FDAS RISK EVALUATION AND MITIGATION STRATEGIES (REMS) INITIATIVE ON PRESCRIPTION PATTERN FOR DRUGS APPROVED UNDER THE REMS PROGRAM AND RELEVANT NON-REMS COMPETITORS

    May 1, 2010, 00:00

  • PGI25 PHARMACOECONOMIC ANALYSIS OF THE EFFECTS OF SECONDARY BACTERIAL RESISTANCE IN THE MULTI-DEPARTMENTAL HOSPITAL ON TREATMENT EFFICACY IN COMPLICATED ABDOMINAL INFECTIONS

    May 1, 2010, 00:00

  • PCN131 THE COST OF TREATING LUNG CANCER IN THE UNITED STATES- AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2010, 00:00

  • PRS21 ANALYSIS OF CLINICAL EFFICACY AND DIRECT COSTS OF THE SPECIFIC IMMUNOTHERAPY IN POLAND-A THREE-YEAR RETROSPECTIVE STUDY

    May 1, 2010, 00:00

  • PMH38 SOCIETAL COSTS OF OPIOID ABUSE, DEPENDENCE, AND MISUSE IN THE UNITED STATES

    May 1, 2010, 00:00

  • PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY - AN UPDATED ANALYSIS

    May 1, 2010, 00:00

  • PMC9 DATA SCAFFOLDING- A PRAGMATIC APPROACH TO STRUCTURING A LITERATURE REVIEW SPREADSHEET TO MAXIMIZE INFORMATION, FACILITATE REVIEW AND SUPPORT ANALYSIS

    May 1, 2010, 00:00

  • PCV142 COMPARATIVE EFFECTIVENESS REVIEW- DRUG-ELUTING STENTS VERSUS BARE-METAL STENTS FOR ACUTE MYOCARDIAL INFARCTION

    May 1, 2010, 00:00

  • PMS18 RHEUMATOID ARTHRITIS (RA) TREATMENT COSTS AMONG U.S. PATIENTS TREATED WITH INFUSED BIOLOGICS

    May 1, 2010, 00:00

  • PCV24 A META-ANALYSIS OF EFFICACY AND SAFETY OF DALTEPARIN IN THE PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLIC DISEASE (VTE)

    May 1, 2010, 00:00

  • PCV55 DIFFERENCE IN OUTCOMES MEASURES OF PATIENTS WITH VALVULAR AND NON-VALVULAR ATRIAL FIBRILLATION

    May 1, 2010, 00:00

  • PIH34 DRG 237- SPRAINS, STRAINS, THIGH

    May 1, 2010, 00:00

  • PIH4 ASSESSMENT OF MATERNAL MORBIDITY DURING LABOR AND DELIVERY- EVALUATION OF LENGTH OF DELIVERY HOSPITALIZATION STAY OF WOMEN WITH PRE-EXISTING MEDICAL CONDITIONS

    May 1, 2010, 00:00

  • PSY29 MODELING THE COST-EFFECTIVENESS OF BORTEZOMIB FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES

    May 1, 2010, 00:00

  • PCV39 THE PUERTO RICO CARDIOVASCULAR RISK ESTIMATION STUDY (PRCARES)- AN EXPLORATORY ASSESSMENT OF NEW PATIENTS IN PHYSICIANS OFFICES

    May 1, 2010, 00:00

  • PCV19 CLINICAL AND ECONOMIC IMPACT OF A PROGRAM COMBINING COMPREHENSIVE LIPID PROFILING WITH A HEART DISEASE TREATMENT PROTOCOL

    May 1, 2010, 00:00

  • PRS17 COSTS TO TREAT COMMUNITY-ACQUIRED PNEUMONIA EPISODES IN US ADULTS AGED 50 YEARS AND OLDER BY AGE AND RISK

    May 1, 2010, 00:00

  • PCV57 THE DIRECT MEDICAL COSTS OF STROKE IN KOREA

    May 1, 2010, 00:00

  • PMS27 THE COMMON PRACTICE OF ANTI-TNF PRESCRIPTION AND DISPENSING CONDITIONS

    May 1, 2010, 00:00

  • PDB42 PATIENT COMPLIANCE TO EXTENDED-RELEASE VERSUS IMMEDIATERELEASE GLIPIZIDE FOR TYPE 2 DIABETES MELLITUS- A SYSTEMATIC REVIEW

    May 1, 2010, 00:00

  • PMS6 COMPARISON OF COST OF ALLOPURINOL VS FEBUXOSTAT AS A FIRST LINE TREATMENT FOR GOUT

    May 1, 2010, 00:00

  • PCN24 OVERALL SURVIVAL AND DOCETAXEL TREATMENT CYCLES IN PATIENTS WITH METASTATIC PROSTATE CANCER - RESULTS FROM A US ONCOLOGY NETWORK

    May 1, 2010, 00:00

  • PMH14 ALL-CAUSE TREATMENT DISCONTINUATION FOR OLANZAPINE COMPARED TO OTHER ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA- A META-ANALYSIS

    May 1, 2010, 00:00

  • PMH55 CANADIAN COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE VERSUS ORAL ATYPICAL AND CONVENTIONAL DEPOT ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA AT HIGH-RISK OF NON-COMPLIANCE- UPDATED BASED ON NEW CLINICAL DATA

    May 1, 2010, 00:00

  • PM2 EFFECTS OF PRIMARY PROPHYLACTIC G-CSF USE AND DURATION OF USE ON NEUTROPENIA HOSPITALIZATIONS FOR ELDERLY BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY

    May 1, 2010, 00:00

  • ME3 IMPACT OF COST SHARING ON TREATMENT AUGMENTATION IN PATIENTS WITH DEPRESSION

    May 1, 2010, 00:00

  • PGI14 DIRECT AND INDIRECT COSTS OF HEPATITIS C VIRUS (HCV)- COMPARISON OF NON-HCV, UNTREATED HCV, AND PEG-RBV TREATED HCV COHORTS

    May 1, 2010, 00:00

  • PIH30 THE DETERMINANTS OF LIFE EXPECTANCY IN EASTERN MEDITERRANEAN COUNTRIES- AN ANALYSIS OF WORLD HEALTH ORGANIZATION (WHO) DATA

    May 1, 2010, 00:00

  • PMS75 METHODS FOR INTERPRETING TUMOR NECROSIS FACTOR (TNF) BLOCKER DOSING AND TREATMENT PATTERNS FROM PHARMACY AND PROFESSIONAL CLAIMS

    May 1, 2010, 00:00

  • PGI3 PREVALENCE, COSTS AND SERVICES OF COMORBID CONDITIONS ASSOCIATED WITH FUNCTIONAL DYSPEPSIA

    May 1, 2010, 00:00

  • PMH32 IMPACT OF PERSISTENCE WITH BIPOLAR DISORDER TREATMENT REGIMES INVOLVING MOOD STABILIZERS, ANTIPSYCHOTICS, ANTIDEPRESSANT THERAPY

    May 1, 2010, 00:00

  • PHP42 THE ANNUAL HEALTH CARE EXPENDITURES PER CAPITA IN BRAZIL- A COMPARISON BETWEEN THE PUBLIC AND THE PRIVATE HEALTH CARE SYSTEMS

    May 1, 2010, 00:00

  • PIH35 IMPACT OF PREVENTIVE TREATMENT WITH TITRATED DRY CRANBERRY EXTRACT IN A PATIENT SUFFERING FROM RECURRENT CYSTITIS

    May 1, 2010, 00:00

  • PCV1 EFFECT OF BIVALIRUDIN ON CLINICAL OUTCOMES OF STEMI PATIENTS IN AN OBSERVATIONAL DATASET

    May 1, 2010, 00:00

  • PMS44 USTEKINUMAB IMPROVES OVERALL SKIN RESPONSE AND HEALTH-RELATED QUALITY OF LIFE IN A SUBSET OF MODERATE TO SEVERE PSORIASIS PATIENTS WITH PSORIATIC ARTHRITIS- ANALYSIS OF PHOENIX 1 AND 2

    May 1, 2010, 00:00

  • PMH82 OUTCOMES OF SECOND GENERATION ATYPICAL ANTIPSYCHOTICS, FIRST GENERATION ANTIPSYCHOTICS AND ROUTINE OUTPATIENT BEHAVIORAL HEALTH SERVICES IN PREVENTING ARRESTS IN PERSONS WITH SEVERE MENTAL ILLNESS

    May 1, 2010, 00:00

  • PMH72 CONCORDANCE OF COMPUTERIZED SELF-REPORT MEASURES OF DSM-IV-TR MOOD AND ANXIETY DISORDERS COMPARED TO GOLD STANDARD CLINICAL ASSESSMENTS IN PRIMAY CARE

    May 1, 2010, 00:00

  • PDB45 ASSOCIATION BETWEEN HEALTH INSURANCE PLAN TYPE AND MEDICATION POSSESSION RATIOS IN ADULT WORKING AGE PATIENTS WITH TYPE 2 DIABETES MELLITUS

    May 1, 2010, 00:00

  • Extended-Release Trospium Chloride Improves Quality of Life in Overactive Bladder

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease

    Mar 1, 2010, 00:00

  • Health State Survey-Derived Utilities in Cost-Utility Analysis—A Call to Action

    Mar 1, 2010, 00:00

  • A Rapid-Response Economic Evaluation of the UK NHS Cancer Reform Strategy Breast Cancer Screening Program Extension via a Plausible Bounds Approach

    Mar 1, 2010, 00:00

  • Crossing Borders- Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European Countries

    Mar 1, 2010, 00:00

  • Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Brazil- Primary Prevention Analysis in the Public Sector

    Mar 1, 2010, 00:00

  • Labeled versus Unlabeled Discrete Choice Experiments in Health Economics- An Application to Colorectal Cancer Screening

    Mar 1, 2010, 00:00

  • Understanding the Medical and Nonmedical Value of Diagnostic Testing

    Mar 1, 2010, 00:00

  • Reliability and Validity of a Chinese Version's Health-Related Quality of Life Questionnaire for Hepatitis B Patients

    Mar 1, 2010, 00:00

  • Value of Information Analyses of Economic Randomized Controlled Trials- The Treatment of Intermittent Claudication

    Mar 1, 2010, 00:00

  • Analysis of the Association between Metabolic Syndrome and Disease in a Workplace Population over Time

    Mar 1, 2010, 00:00

  • In or Out? Income Losses in Health State Valuations- A Review

    Mar 1, 2010, 00:00

  • Health State Valuations of Patients and the General Public Analytically Compared- A Meta-Analytical Comparison of Patient and Population Health State Utilities

    Mar 1, 2010, 00:00

  • The Cost-Effectiveness of an Extended Course (12 + 12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States- An Extension and Update to the BENESCO Model

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of 21 Alternative Cervical Cancer Screening Strategies

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of Using Recombinant Human Thyroid-Stimulating Hormone before Radioiodine Ablation for Thyroid Cancer- The Canadian Perspective

    Mar 1, 2010, 00:00

  • The Impact of Differences in EQ-5D and SF-6D Utility Scores on the Acceptability of Cost–Utility Ratios- Results across Five Trial-Based Cost–Utility Studies

    Mar 1, 2010, 00:00

  • Valuation of EQ-5D Health States in Poland- First TTO-Based Social Value Set in Central and Eastern Europe

    Mar 1, 2010, 00:00

  • Erratum

    Mar 1, 2010, 00:00

  • Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature

    Mar 1, 2010, 00:00

  • A Median Model for Predicting United States Population-Based EQ-5D Health State Preferences

    Mar 1, 2010, 00:00

  • Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease- A Modeled Analysis

    Mar 1, 2010, 00:00

  • Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over 5 Years or More

    Mar 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses- An Industry Perspective- The ISPOR Drug Cost Task Force Report—Part V

    Jan 1, 2010, 00:00

  • A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia

    Jan 1, 2010, 00:00

  • Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical Setting

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses- An International Perspective- The ISPOR Drug Cost Task Force Report—Part VI

    Jan 1, 2010, 00:00

  • Beyond AWP … Way Beyond

    Jan 1, 2010, 00:00

  • What's in a Perspective?

    Jan 1, 2010, 00:00

  • Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 Diabetes

    Jan 1, 2010, 00:00

  • Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma

    Jan 1, 2010, 00:00

  • The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical Trials

    Jan 1, 2010, 00:00

  • Budget Impact Analysis of Thrombolysis for Stroke in Spain- A Discrete Event Simulation Model

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses- A Societal Perspective- The ISPOR Drug Cost Task Force Report—Part II

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses- Issues and Recommendations- The ISPOR Drug Cost Task Force Report—Part I

    Jan 1, 2010, 00:00

  • Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma

    Jan 1, 2010, 00:00

  • Erratum

    Jan 1, 2010, 00:00

  • Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United States

    Jan 1, 2010, 00:00

  • Psychometric Development of the Individualized Retinopathy-Dependent Quality of Life Questionnaire (RetDQoL)

    Jan 1, 2010, 00:00

  • A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple Countries

    Jan 1, 2010, 00:00

  • Relationship between Health-Related Quality of Life, Pain, and Functional Disability in Neuropathic Pain Patients with Failed Back Surgery Syndrome

    Jan 1, 2010, 00:00

  • Calibration of Disease Simulation Model Using an Engineering Approach

    Jan 1, 2010, 00:00

  • The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment- Modeled German Cost-Effectiveness Analysis

    Jan 1, 2010, 00:00

  • Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence Symptoms

    Jan 1, 2010, 00:00

  • ISPOR Code of Ethics

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses- A Managed Care Perspective- The ISPOR Drug Cost Task Force Report—Part III

    Jan 1, 2010, 00:00

  • Cost–Benefit Analysis of Preventing Nosocomial Bloodstream Infections among Hemodialysis Patients in Canada in 2004

    Jan 1, 2010, 00:00

  • Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses- Medicare, Medicaid and Other US Government Payers Perspectives- The ISPOR Drug Cost Task Force Report—Part IV

    Jan 1, 2010, 00:00

  • The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New Zealand

    Jan 1, 2010, 00:00

  • Instrumental Variables in Influenza Vaccination Studies- Mission Impossible?!

    Jan 1, 2010, 00:00

  • Pharmacoeconomic Guidelines and Their Implementation in the Positive List System in South Korea

    Nov 1, 2009, 00:00

  • Cost-Effectiveness Analysis of Oseltamivir for Influenza Treatment Considering the Virus Emerging Resistant to the Drug in Japan

    Nov 1, 2009, 00:00

  • Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification- The ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force R ...

    Nov 1, 2009, 00:00

  • Cost-Effectiveness Study Comparing Imatinib with Interferon-α for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Health-Care System Perspective (CPHSP)

    Nov 1, 2009, 00:00

  • A Survey of Knowledge on Diabetes in the Central Region of Thailand

    Nov 1, 2009, 00:00

  • Celebrating the 2nd Asia Special Issue- ISPOR Reaching a Six-Year Milestone in the Asia-Pacific Region

    Nov 1, 2009, 00:00

  • Probabilistic Sensitivity Analysis- Be a Bayesian

    Nov 1, 2009, 00:00

  • South Korean Time Trade-Off Values for EQ-5D Health States- Modeling with Observed Values for 101 Health States

    Nov 1, 2009, 00:00

  • A Concept Taxonomy and an Instrument Hierarchy- Tools for Establishing and Evaluating the Conceptual Framework of a Patient-Reported Outcome (PRO) Instrument as Applied to Product Labeling Claims

    Nov 1, 2009, 00:00

  • Reviewer Acknowledgment

    Nov 1, 2009, 00:00

  • Patient Experiences of Continuity of Cancer Care- Development of a New Medical Care Questionnaire (MCQ) for Oncology Outpatients

    Nov 1, 2009, 00:00

  • Assessment of Total Economic Burden of Chronic Hepatitis B (CHB)-Related Diseases in Beijing and Guangzhou, China

    Nov 1, 2009, 00:00

  • The Current Capacity and Future Development of Economic Evaluation for Policy Decision-Making- A Survey among Researchers and Decision-Makers in Thailand

    Nov 1, 2009, 00:00

  • Evidence-Based Decision on Medical Technologies in Asia Pacific- Experiences from India, Malaysia, Philippines, and Pakistan

    Nov 1, 2009, 00:00

  • Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea

    Nov 1, 2009, 00:00

  • International Comparisons in Valuing EQ-5D Health States- A Review and Analysis

    Nov 1, 2009, 00:00

  • Evidence-Based Decision-Making on Medical Technologies in China, Japan, and Singapore

    Nov 1, 2009, 00:00

  • Cost-Effectiveness of Long-Acting Risperidone Injection versus Alternative Atypical Antipsychotic Agents in Patients with Schizophrenia in China

    Nov 1, 2009, 00:00

  • A Catalogue of EQ-5D Utility Weights for Chronic Diseases among Noninstitutionalized Community Residents in Korea

    Nov 1, 2009, 00:00

  • Using Economic Evaluation in Policy Decision-Making in Asian Countries- Mission Impossible or Mission Probable?

    Nov 1, 2009, 00:00

  • Costs and Health Utilities Associated with Extremely Preterm Birth- Evidence from the EPICure Study

    Nov 1, 2009, 00:00

  • ISPOR Health Policy Council Proposed Good Research Practices for Comparative Effectiveness Research- Benefit or Harm?

    Nov 1, 2009, 00:00

  • Relapse and Long-Acting Injectable Risperidone- A 1-Year Mirror Image Study with a National Claims Database in Taiwan

    Nov 1, 2009, 00:00

  • Good Research Practices for Comparative Effectiveness Research- Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources- The ISPOR Good Research Practices for Retrospective D ...

    Nov 1, 2009, 00:00

  • Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia

    Nov 1, 2009, 00:00

  • The Economic Value of Innovative Treatments over the Product Life Cycle- The Case of Targeted Trastuzumab Therapy for Breast Cancer

    Nov 1, 2009, 00:00

  • Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life Questionnaire

    Nov 1, 2009, 00:00

  • Growing Application of Pharmacoeconomics and Outcomes Research in Health-Care Decision-Making in the Asia-Pacific Region

    Nov 1, 2009, 00:00

  • Economic Evaluation of Universal Infant Vaccination with 7vPCV in Hong Kong

    Nov 1, 2009, 00:00

  • A Time-Cost Augmented Economic Evaluation of Oral Deferasirox versus Infusional Dereroxmine for Patients with Iron Overload in South Korea

    Nov 1, 2009, 00:00

  • Evidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems- Thailand, South Korea, and Taiwan

    Nov 1, 2009, 00:00

  • Good Research Practices for Comparative Effectiveness Research- Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources- The International Society for Pharmacoecon ...

    Nov 1, 2009, 00:00

  • Valuation of the Economic Benefits of Human Papillomavirus Vaccine in Taiwan

    Nov 1, 2009, 00:00

  • Cost-Effectiveness of Using Clinical Risk Factors with and without DXA for Osteoporosis Screening in Postmenopausal Women

    Nov 1, 2009, 00:00

  • The Imperative to Improve

    Nov 1, 2009, 00:00

  • An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer

    Nov 1, 2009, 00:00

  • Estimating Medical Expenditure Associated with Osteoporotic Hip Fracture in Elderly Korean Women Based on the National Health Insurance Claims Database 2002–2004

    Nov 1, 2009, 00:00

  • On Guidelines for Comparative Effectiveness Research Using Nonrandomized Studies in Secondary Data Sources

    Nov 1, 2009, 00:00

  • Reviewer Acknowledgments

    Nov 1, 2009, 00:00

  • The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report

    Nov 1, 2009, 00:00

  • Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea

    Nov 1, 2009, 00:00

  • Psychometric Evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)—A Measure of Symptom Distress

    Nov 1, 2009, 00:00

  • The Impact of Health Literacy on Health-Related Quality of Life (HRQoL) and Utility Assessment among Patients with Rheumatic Diseases

    Nov 1, 2009, 00:00

  • Good Research Practices for Comparative Effectiveness Research- Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources- The ISPOR Good Research Practices for Retrospective Database Analy ...

    Nov 1, 2009, 00:00

  • Impact of Diabetes Mellitus (DM) on the Health-Care Utilization and Clinical Outcomes of Patients with Stroke in Singapore

    Nov 1, 2009, 00:00

  • The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III

    Nov 1, 2009, 00:00

  • Establishing Optimal Requirements for Content Validity- A Work in Progress

    Nov 1, 2009, 00:00

  • Economic Impact on Health-Care Costs Related to Major Diseases Including HIV/AIDS due to Alcohol Drinking among Thai Populations

    Nov 1, 2009, 00:00

  • Too Much Ado about Instrumental Variable Approach- Is the Cure Worse than the Disease?

    Nov 1, 2009, 00:00

  • Psychometric Properties of a German Version of the “Satisfaction with Information about Medicines Scale” (SIMS-D)

    Nov 1, 2009, 00:00

  • Mapping the Cancer-Specific EORTC QLQ-C30 to the Preference-Based EQ-5D, SF-6D, and 15D Instruments

    Nov 1, 2009, 00:00

  • Evaluation of Cost-Utility of Varenicline Compared with Existing Smoking Cessation Therapies in South Korea

    Nov 1, 2009, 00:00

  • PCN118 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER- DESCRIPTION OF A NICE SUBMISSION

    Oct 1, 2009, 00:00

  • PSY55 IMPACT OF THE NEW RECOMMENDATIONS IN THE USE OF PROTHROMBIN COMPLEX CONCENTRATES AND VITAMIN K ANTAGONISTS IN FRANCE- ILLUSTRATION OF THE GUIDELINES RESPECT IN HOSPITAL AND ITS ECONOMIC CONSEQUENCES

    Oct 1, 2009, 00:00

  • PCV117 COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND-A DISCRETE EVENT SIMULATION MODELLING

    Oct 1, 2009, 00:00

  • PCV111 A PATIENTS VIEW OF THE COST-EFFECTIVENESS OF USING LOWDOSE ASPIRIN FOR CVD (CARDIOVASCULAR DISEASE) PRIMARY PREVENTION IN MIDDLE-AGED MEN IN THE UK

    Oct 1, 2009, 00:00

  • PCN151 CROSS-REGIONAL FLOWS OF CANCER PATIENTS IN GREECE- URBANIZATION OF CANCER TREATMENT

    Oct 1, 2009, 00:00

  • DE1 MARKET CONCENTRATION AND ITS CROSS-LINKAGE WITH THE CONSUMPTION OF ACE INHIBITORS AND ARBS

    Oct 1, 2009, 00:00

  • PMS19 BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2009, 00:00

  • PCN71 COST-EFFECTIVENESS OF RITUXIMAB COMBINED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN FRANCE

    Oct 1, 2009, 00:00

  • PRS7 IMPACT OF COUGH AND/OR SPUTUM SYMPTOMS ON THE BURDEN OF COPD IN EUROPE AND THE USA- A CROSS-SECTIONAL, OBSERVATIONAL STUDY

    Oct 1, 2009, 00:00

  • PCN91 LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER

    Oct 1, 2009, 00:00

  • PCN73 COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY

    Oct 1, 2009, 00:00

  • PCN120 COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND

    Oct 1, 2009, 00:00

  • PCV149 ASSESSMENT OF QUALITY OF LIFE AMONG PATIENTS WITH HYPERTENSION AND DIABETES TYPE 2

    Oct 1, 2009, 00:00

  • PCN27 COST MINIMIZATION ANALYSIS OF TEGAFUR-URACIL ASSOCIATED TO LEUCOVORIN (UFT/LV) VERSUS CAPECITABINE ALONE FOR METASTATIC COLORECTAL CANCER UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCV16 COMPARATIVE EFFICACY OF LOSARTAN AND IRBESARTAN IN HYPERTENSIVE PATIENTS AT SARABURI HOSPITAL, THAILAND 2007

    Oct 1, 2009, 00:00

  • PMS27 DIRECT AND INDIRECT COSTS OF RHEUMATOID ARTHRITIS MANAGEMENT IN POLAND

    Oct 1, 2009, 00:00

  • MO6 MODELLING COST EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS- A NOVEL APPROACH

    Oct 1, 2009, 00:00

  • PG18 COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS PROTON PUMP INHIBITORS (IV PPI) FOR THE PREVENTION OF GASTRIC OR DUODENAL ULCER REBLEEDING AFTER THERAPEUTIC ENDOSCOPY

    Oct 1, 2009, 00:00

  • PIH14 THE COST-EFFECTIVENESS OF ETONOGESTREL/ETHINYL ESTRADIOL VAGINAL RING IN SCOTLAND

    Oct 1, 2009, 00:00

  • PHP90 PATIENT-HEALTH CARE PROVIDER COMMUNICATION- IMPACT ON PATIENT SATISFACTION ON THE QUALITY OF HEALTH SERVICE

    Oct 1, 2009, 00:00

  • PSY24 A COST CONSEQUENCE EVALUATION OF TWO MODELS OF CARE OF OUTPATIENTS WITH CHRONIC NEUROPATHIC PAIN IN NEUROLOGY SETTINGS IN SPAIN- GENERAL CLINICS VERSUS SPECIALIZED PAIN CLINICS

    Oct 1, 2009, 00:00

  • PMH28 INITIAL PRESCRIPTION DOSE OF DULOXETINE AND HOSPITALIZATION AND HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Oct 1, 2009, 00:00

  • PDB52 PATIENT TREATMENT SATISFACTION OF TYPE 2 DIABETIC PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS GLARGINE OR DETEMIR AS BASAL INSULIN- RESULTS FROM THE LIVE-COM STUDY

    Oct 1, 2009, 00:00

  • PMC58 EVALUATING THE INFLUENCE OF PHYSICAL ACTIVITY ON THE SOCIAL AND ENVIRONMENTAL DOMAINS OF QUALITY OF LIFE

    Oct 1, 2009, 00:00

  • PCV44 HEART FAILURE IN OLDER PEOPLE- A STUDY OF FACTORS THAT LEAD TO HOSPITALISATION

    Oct 1, 2009, 00:00

  • PCN121 COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND

    Oct 1, 2009, 00:00

  • PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HE ...

    Oct 1, 2009, 00:00

  • PP1 A SYSTEMATIC REVIEW OF THE ANALYTIC HIERARCHY PROCESS IN HEALTH CARE DECISION MAKING

    Oct 1, 2009, 00:00

  • PHP31 A POLICY FRAMEWORK FOR FUNDING DRUGS FOR RARE DISEASES

    Oct 1, 2009, 00:00

  • PCV113 COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN IN EXTENDED PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN MAJOR ORTHOPEDIC SURGERY IN POLAND

    Oct 1, 2009, 00:00

  • PCV2 INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS WITH UNTREATED PRIMARY HYPERPARATHYROIDISM

    Oct 1, 2009, 00:00
  • «
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147 (current)
  • 148
  • 149
  • 150
  • »